Related references
Note: Only part of the references are listed.The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC
Eliza Guti et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)
Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility
Christian M. Orr et al.
SCIENCE IMMUNOLOGY (2022)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Immunogenicity Risk Profile of Nanobodies
Chloe Ackaert et al.
FRONTIERS IN IMMUNOLOGY (2021)
Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC
Henk van Faassen et al.
MOLECULAR PHARMACEUTICS (2021)
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
Sarah B. Reusing et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Fc γ receptor compositional heterogeneity: Considerations for immunotherapy development
Adam W. Barb
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Signaling through the Inhibitory Fc Receptor FcγRIIB Induces CD8+ T Cell Apoptosis to Limit T Cell Immunity
Anna B. Morris et al.
IMMUNITY (2020)
Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs
Alicia M. Chenoweth et al.
IMMUNOLOGY AND CELL BIOLOGY (2020)
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Soo-Chin Lee et al.
CLINICAL CANCER RESEARCH (2020)
Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
Kristina Ellwanger et al.
MABS (2019)
Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility
Xiaobo Liu et al.
NATURE COMMUNICATIONS (2019)
FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils
Louise W. Treffers et al.
FRONTIERS IN IMMUNOLOGY (2019)
An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages
Tae Hyun Kang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Nanobodies and Cancer: Current Status and New Perspectives
Alessandro Allegra et al.
CANCER INVESTIGATION (2018)
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
Hanke L. Matlung et al.
CELL REPORTS (2018)
Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance
Ranferi Ocana-Guzman et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
A single amino acid distorts the Fc receptor IIIb/CD16b structure upon binding immunoglobulin G1 and reduces affinity relative to CD16a
Jacob T. Roberts et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers
Roghaye Arezumand et al.
FRONTIERS IN IMMUNOLOGY (2017)
Nanobodies as therapeutics: big opportunities for small antibodies
Sophie Steeland et al.
DRUG DISCOVERY TODAY (2016)
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
Caroline Jochems et al.
ONCOTARGET (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics
Martin Felices et al.
BLOOD (2016)
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
Uwe Reusch et al.
MABS (2014)
Modulation of NKG2D-ligand Cell Surface Expression Enhances Immune Cell Therapy of Cancer
Baocheng Huang et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer
Zsuzsanna Palyi-Krekk et al.
EUROPEAN JOURNAL OF CANCER (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Mark Barok et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Polymorphisms in FcγRIIIA (CD 16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia
SP Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Glycosylation of FcγRIII in N163 as mechanism of regulating receptor affinity
B Drescher et al.
IMMUNOLOGY (2003)
Adaptive evolution of variable region genes encoding an unusual type of immunoglobulin in camelids
C Su et al.
MOLECULAR BIOLOGY AND EVOLUTION (2002)
Share Paper
